Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update

Applied Therapeutics, Inc. (NASDAQ:APLT) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 19,160,000 shares, an increase of 5.6% from the December 15th total of 18,150,000 shares. Based on an average daily trading volume, of 5,880,000 shares, the days-to-cover ratio is presently 3.3 days.

Applied Therapeutics Stock Performance

APLT traded up $0.03 during trading on Friday, hitting $0.65. The stock had a trading volume of 8,517,643 shares, compared to its average volume of 6,011,855. Applied Therapeutics has a twelve month low of $0.60 and a twelve month high of $10.62. The company’s 50-day moving average price is $3.32 and its 200 day moving average price is $5.59.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on APLT shares. UBS Group reiterated a “neutral” rating and set a $2.00 price target (down from $13.00) on shares of Applied Therapeutics in a research report on Monday, December 2nd. Royal Bank of Canada dropped their target price on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. Robert W. Baird decreased their price target on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, November 29th. Citigroup dropped their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Finally, William Blair lowered Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Applied Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.10.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in APLT. SG Americas Securities LLC raised its stake in shares of Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after buying an additional 25,601 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Applied Therapeutics by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock valued at $268,000 after acquiring an additional 47,983 shares during the period. Barclays PLC boosted its position in shares of Applied Therapeutics by 186.1% during the 3rd quarter. Barclays PLC now owns 200,012 shares of the company’s stock worth $1,702,000 after purchasing an additional 130,102 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Applied Therapeutics during the 3rd quarter worth $149,000. Finally, XTX Topco Ltd purchased a new position in shares of Applied Therapeutics in the 3rd quarter valued at about $531,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.